Eskild Colding‐Jørgensen

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

David Wilkinson, Kristian Windfeld, Eskild Colding‐Jørgensen · The Lancet Neurology · 2014 · 159 citations

Placebo-controlled Phase 2, Neurodegenerative Diseases, Alzheimer's Disease +13

Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype

Morten Dunø, Eskild Colding‐Jørgensen, Morten Grunnet et al. · European Journal of Human Genetics · 2004 · 76 citations · Full text

Allelic Variant, Allelic Expression, Developmental Biology +7

Autosomal dominant monosymptomatic myotonia permanens

Eskild Colding‐Jørgensen, John Vissing · Neurology · 2006 · 40 citations

Scn4a Gene, Clinical Disorders, Rare Diseases +11

Decrement of compound muscle action potential is related to mutation type in myotonia congenita

Eskild Colding‐Jørgensen, Morten Dunø, Marianne Schwartz et al. · Muscle & Nerve · 2003 · 39 citations

On the evidence of auditory evoked magnetic fields as an objective measure of tinnitus

Eskild Colding‐Jørgensen, Martin Lauritzen, N. J. Johnsen et al. · Electroencephalography and Clinical Neurophysiology · 1992 · 29 citations

Cognitive Science, Health Sciences, Neurophysiology +11